The Chinese University of Hong Kong

Joseph Jao Yiu Sung

Jun Yu

Qiaoyi Liang

Xiaoxing Li

Yujuan Dong

Ming Li

Chi Chun Wong

Kenneth Ka Ho Lee

Zheng Li

Philip Wai Yan Chiu

Edmund Cheung

Calvin Sze Hang Ng

Shiyan Wang

Simon Siu Man Ng

Siu Man Simon Ng

Lixia Xu

John Elsby Sanderson

Jack Chun Yiu Cheng

Edmund Ngai Man Cheung

Provided is a non-invasive method for diagnosing colorectal cancer in a subject by detecting enrichment or reduction of certain bacterial species. A kit and device useful for such methods are also provided. In addition, a method for reducing the risk of colon cancer by regulating the pertinent bacterial species in human colon is also provided.

Fecal bacterial markers for colorectal cancer

The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the REC8 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing REC8 gene expression or activity. Lastly, a highly sensitive and accurate detection method is provided for rapid determination of REC8 gene methylation status.

Tumor suppressor REC8 as a biomarker for gastric cancer

A new steerable endoscope for minimally invasive surgery is provided. The endoscope system includes: a wireless steerable endoscope (), an external magnetic controller () and an image/video display (). The wireless steerable endoscope () could be inserted through an incision (-) on the body skin () and be anchored/steered inside the body cavity by the external magnetic controller (). It is shaftless, wireless, and can be steered inside the body, operating in a remote manner. Compared with existing endoscopes, it neither requires additional incision nor does it occupy trocar or port space. Without the endoscope shaft, the surgical access trauma and incision size can potentially be reduced, avoiding endoscope-instrument fencing. It can be placed remotely from the access incision, providing an improved and wider field of view. It is soft-bodied and compact in structure, therefore safety is high. More than one wireless endoscope can be placed into the operating cavity, providing simultaneous multiple video images of different viewing angles. These features allow safer, more efficient and less traumatic surgery by reducing trocar size or number.

Wireless magnetically steerable endoscope

The present invention provides methods for assessing the likelihood of effectiveness of chemotherapy such as oxaliplatin treatment in colorectal cancer patients as well as their survival prospect by determining the level of miR-133a in the cancer tissue. A kit useful for such methods are also provided.

miR-133a as a marker for colorectal cancer

The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the SCNN1B gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing SCNN1B gene expression or activity.

Biomarker SCNN1B for gastric cancer

The present invention provides a method for diagnosing of colorectal cancer in a subject and a method for determining risk of recurrence of colorectal cancer among colorectal cancer patients by detecting overexpression of the RNF6 gene, which in some cases is due to a higher than normal copy number of the genomic sequence of this gene. A kit and device useful for such methods are also provided. In addition, the present invention provides a method for treating colon cancer by suppressing RNF6 gene expression or activity.

Biomarker RNF6 for colorectal cancer

The present invention provides a method for diagnosing and determining prognosis of colorectal cancer in a subject by detecting suppressed expression of the VSTM2A gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating colorectal cancer by increasing VSTM2A gene expression or activity.

Tumor suppressor VSTM2A as a biomarker for colorectal cancer

The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the FOXF2 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing FOXF2 gene expression or activity.

Biomarker FOXF2 for gastric cancer

The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the ZNF545 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing ZNF545 gene expression or activity.

Epigenetic biomarker ZNF545 for diagnosing and prognosis of gastric cancer

The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the DACT1 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing DACT1 gene expression or activity.

Biomarker DACT1 for gastric cancer

The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the ADAMTS9 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing ADAMTS9 gene expression or activity.

Epigenetic biomarker ADAMTS9 for diagnosis and prognosis of gastric cancer

The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the BCL6B gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing BCL6B gene expression or activity.

Biomarker for gastric cancer

In embodiments the expression or methylation of the PAX5 gene is used as a marker for the diagnosis and prognosis of gastric cancer. In further embodiments methods for detecting gastric cancer are disclosed as are methods for inhibiting the growth of gastric cancer.

Marker for gastric cancer and method for detecting gastric cancer

An organic extract ofvar. (EGJ), and a pharmaceutical composition comprising the same. The organic EGJ has been identified to show potent dual effects on stimulating early growth (less than 48 hours) of new vessels both in ischemic heart muscles and in infracted heart muscles, and on triggering myocardial regeneration in myocardial infarction, and therefore, may be used in the treatment of ischemic diseases in human being or animals including ischemic heart disease and ischemic limbs, and damaged myocardium associated diseases.

Growing community of inventors

Ma On Shan, China

Joseph Jao Yiu Sung